Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury

Circulation

Volumn 137, Issue 12, 2018, Pages 1236-1245

  Chapman, Andrew R ^a   Shah, Anoop S V ^a   Lee, Kuan Ken ^a   Anand, Atul ^a   Francis, Oliver ^a   Adamson, Philip ^a   McAllister, David A ^b   Strachan, Fiona E ^a   Newby, David E ^a   Mills, Nicholas L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Myocardial injury; Troponin; Type 2 myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; TROPONIN I; WARFARIN; BIOLOGICAL MARKER;

AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE INJURY; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MORTALITY RISK; PRIORITY JOURNAL; TYPE 1 MYOCARDIAL INFARCTION; TYPE 2 MYOCARDIAL INFARCTION; BLOOD; CARDIAC MUSCLE; CAUSE OF DEATH; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; MORTALITY; NECROSIS; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CAUSE OF DEATH; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TROPONIN I; UP-REGULATION;

EID: 85047140290     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.031806     Document Type: Article

References (34)

1. White HD, Thygesen K, Alpert JS, Jaffe AS. Clinical implications of the third universal definition of myocardial infarction. Heart. 2014;100:424-432. Doi: 10.1136/heartjnl-2012-302976.
2. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasché P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, FilippatosG, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012;33:2551-2567. Doi: 10.1093/eurheartj/ehs184.
3. Alpert JS, Thygesen KA. The case for a revised definition of myocardial infarction: the ongoing conundrum of type 2 myocardial infarction vs myocardial injury. JAMA Cardiol. 2016;1:249-250. Doi: 10.1001/jamacardio. 2016.0543.
4. Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM, Layden E, Anand A, Fersia O, Joshi NV, Walker S, Jaffe AS, Fox KA, Newby DE, Mills NL. Sensitive troponin assay and the classification of myocardial infarction. Am J Med. 2015;128:493.e3-501.e3. Doi: 10.1016/j.amjmed. 2014.10.056.
5. Javed U, Aftab W, Ambrose JA, Wessel RJ, Mouanoutoua M, Huang G, Barua RS, Weilert M, Sy F, Thatai D. Frequency of elevated troponin I and diagnosis of acute myocardial infarction. Am J Cardiol. 2009;104:9-13. Doi: 10.1016/j.amjcard.2009.03.003.
6. El-Haddad H, Robinson E, Swett K, Wells GL. Prognostic implications of type 2 myocardial infarctions. World J Cardiovasc Dis. 2012;2:237-241.
7. Sarkisian L, Saaby L, Poulsen TS, Gerke O, Jangaard N. Clinical characteristics and outcomes of patients with myocardial infarction, myocardial injury, and nonelevated troponins. Am J Med. 2016;129:446.e5-446.e21.
8. Saaby L, Poulsen TS, Diederichsen AC, Hosbond S, Larsen TB, Schmidt H, Gerke O, Hallas J, Thygesen K, Mickley H. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. Am J Med. 2014;127:295-302. Doi: 10.1016/j.amjmed.2013.12.020.
9. Stein GY, Herscovici G, Korenfeld R, Matetzky S, Gottlieb S, Alon D, Gevrielov-Yusim N, Iakobishvili Z, Fuchs S. Type-II myocardial infarction-patient characteristics, management and outcomes. PLoS One. 2014;9:e84285. Doi: 10.1371/journal.pone.0084285.
10. Sandoval Y, Smith SW, Sexter A, Thordsen SE, Bruen CA, Carlson MD, Dodd KW, Driver BE, Hu Y, Jacoby K, Johnson BK, Love SA, Moore JC, Schulz K, Scott NL, Apple FS. Type 1 and 2 myocardial infarction and myocardial injury: clinical transition to high-sensitivity cardiac troponin I. Am J Med. 2017;130:1431.e4?1439.e4. Doi: 10.1016/j.amjmed.2017.05.049.
11. Neumann JT, Sörensen NA, Rübsamen N, Ojeda F, Renné T, Qaderi V, Teltrop E, Kramer S, Quantius L, Zeller T, Karakas M, Blankenberg S, Westermann D. Discrimination of patients with type 2 myocardial infarction. Eur Heart J. 2017;38:3514?3520. Doi: 10.1093/eurheartj/ehx457.
12. Gaggin HK, Liu Y, Lyass A, van Kimmenade RR, Motiwala SR, Kelly NP, Mallick A, Gandhi PU, Ibrahim NE, Simon ML, Bhardwaj A, Belcher AM, Harisiades JE, Massaro JM, D'Agostino RB Sr, Januzzi JL Jr. Incident type 2 myocardial infarction in a cohort of patients undergoing coronary or peripheral arterial angiography. Circulation. 2017;135:116-127. Doi: 10.1161/CIRCULATIONAHA.116.023052.
13. Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, Shah AS, Paterson E, MacLeod M, Graham C, Walker S, Denvir MA, Fox KA, Newby DE. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA. 2011;305:1210-1216. Doi: 10.1001/jama.2011.338.
14. Yelland LN, Salter AB, Ryan P. Relative risk estimation in randomized controlled trials: a comparison of methods for independent observations. Int J Biostat. 2011;7:1-31.
15. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
16. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015. Https://www.R-project.org/.
17. Melberg T, Burman R, Dickstein K. The impact of the 2007 ESC-ACCAHA-WHF universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study. Int J Cardiol. 2010;139:228-233. Doi: 10.1016/j.ijcard.2008.10.021.
18. Shah AS, Griffiths M, Lee KK, McAllister DA, Hunter AL, Ferry AV, Cruikshank A, Reid A, Stoddart M, Strachan F, Walker S, Collinson PO, Apple FS, Gray AJ, Fox KA, Newby DE, Mills NL. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ. 2015;350:g7873.
19. Smith SW, Diercks DB, Nagurney JT, Hollander JE, Miller CD, Schrock JW, Singer AJ, Apple FS, McCullough PA, Ruff CT, Sesma A Jr, Peacock WF. Central versus local adjudication of myocardial infarction in a cardiac biomarker trial. Am Heart J. 2013;165:273.e1-279.e1. Doi: 10.1016/j. Ahj.2012.12.012.
20. Sandoval Y, Thordsen SE, Smith SW, Schulz KM, Murakami MM, Pearce LA, Apple FS. Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality risk. Eur Heart J Acute Cardiovasc Care. 2014;3:317-325. Doi: 10.1177/2048872614538411.
21. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B; TOTAL-AMI study group. Impact on long-term mortality of presence of obstructive coronary artery disease and classification of myocardial infarction. Am J Med. 2016;129:398-406. Doi: 10.1016/j.amjmed.2015.11.035.
22. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, Thygesen K, Mickley H. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med. 2013;126:789-797. Doi: 10.1016/j.amjmed.2013.02.029.
23. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B; TOTAL-AMI study group. Type 2 myocardial infarction in clinical practice. Heart. 2015;101:101-106. Doi: 10.1136/heartjnl-2014-306093.
24. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, Bonaca MP, Ruff CT, Scirica BM, McCabe CH, Antman EM, Braunwald E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009;119:2758-2764. Doi: 10.1161/CIRCULATIONAHA. 108.833665.
25. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, Morrow DA. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012;125:577-583. Doi: 10.1161/CIRCULATIONAHA.111.041160.
26. Sandoval Y, Thygesen K. Myocardial infarction type 2 and myocardial injury. Clin Chem. 2017;63:101-107. Doi: 10.1373/clinchem.2016.255521.
27. Sandoval Y. Editorial commentary: Improving our understanding of type 2 myocardial infarction and myocardial injury. Trends Cardiovasc Med. 2017;27:418-419. Doi: 10.1016/j.tcm.2017.03.007.
28. Collinson P, Lindahl B. Type 2 myocardial infarction: the chimaera of cardiology? Heart. 2015;101:1697-1703. Doi: 10.1136/heartjnl-2014-307122.
29. Chapman AR, Mills NL. Refining the diagnosis of type 2 myocardial infarction. JAMA Cardiol. 2017;2:106. Doi: 10.1001/jamacardio.2016.3698.
30. Chapman AR, Adamson PD, Mills NL. Assessment and classification of patients with myocardial injury and infarction in clinical practice. Heart. 2017;103:10-18. Doi: 10.1136/heartjnl-2016-309530.
31. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher D, Sabti Z, Puelacher C, Rubini Giménez M, Kozhuharov N, Strebel I, Sazgary L, Schneider D, Jann J, du Fay de Lavallaz J, Miró Ò, Martin-Sanchez FJ, Morawiec B, Kawecki D, Muzyk P, Keller DI, Geigy N, Osswald S, Reichlin T, Mueller C; APACE Investigators. Effect of definition on incidence and prognosis of type 2 myocardial infarction. J Am Coll Cardiol. 2017;70:1558-1568. Doi: 10.1016/j.jacc.2017.07.774.
32. Ambrose JA, Loures-Vale A, Javed U, Buhari CF, Aftab W. Angiographic correlates in type 1 and 2 MI by the universal definition. JACC Cardiovasc Imaging. 2012;5:463-464. Doi: 10.1016/j.jcmg.2011.12.016.
33. Januzzi JL, Sandoval Y. The many faces of type 2 myocardial infarction. J Am Coll Cardiol. 2017;70:1569-1572. Doi: 10.1016/j.jacc.2017.07.784.
34. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification: Clinical Guideline [CG181]. Https://www.nice.org.uk/guidance/cg181/